Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Lexicon Pharma target raised to $38 at Wedbush (16.04)Wedbush raises their LXRX tgt to $38 from $33. Firm notes that even with FDA approval of LXRX's lead drug achieved, they still see several clinical and regulatory catalysts for LXRX during the coming months that could lift shares. In addition to the launch of XERMELO, firm sees data presentations of the InTandem 1&2 results at ADA (June 9-13, San Diego), release of 52-week pivotal extension results from InTandem 1, 2 and 3 in Mid:17, and potential early indication that the FDA may consider reviewing sotagliflozin for T1D alone in Q3:17 as catalysts in the future. LXRX is on the Wedbush Best Ideas List (BIL).</td> </tr></table>"